Search Results

SymBiosis Capital Management, LLC (“SymBiosis”) and HealthTech Arkansas today announced the formation of BioAR Trial, an accelerator program to help biotherapeutics companies in late pre-clinical stages of development bring groundbreaking therapies to market faster, while increasing Arkansans’ access to cutting-edge clinical care and innovative medicines.

SymBiosis , an investment firm focused on advancing biotherapeutics innovations, announced today that Dr. Jahan Ali, PhD has joined the firm as Vice President of Business Development.

SymBiosis Capital Management, LLC (“SymBiosis”) today announced its launch as a newly independent venture capital firm focused on advancing biotherapeutics innovations.

Aardvark Therapeutics, Inc. announces an $85 million oversubscribed Series C financing led by Decheng Capital, with participation from Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Fitzgerald & Co., Silver Arc Private Capital, The Prader-Willi Syndrome Association – USA, and existing investors, including Vickers Venture Partners and the Foundation for Prader-Willi Research.

The 2023 China Gut Conference, held from May 20-22, 2023, successfully wrapped up at the China National Convention Center in Beijing.

Metagenomi, a genetic medicines company with a versatile portfolio of wholly owned, next-generation gene editing systems, today announced the close of a Series B extension financing, co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors.

Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) focused on viral vector drug substance production, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable viral vector drug products, today announced the successful completion of their collaboration to develop synergistic and world leading capabilities.

MaaT Pharma, a French clinical-stage biotech company specialized in the development of microbiome-based therapies aiming to restore the microbiome/immune system symbiosis in oncology patients, announced that its MEPA program was awarded a EURO 1.9 million grant from the Plan France Relance.

Siolta Therapeutics, a clinical-stage biotech company, has announced the completion of a $12 million Series C financing round.